Eagle Health Investments LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001842545

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 22 positions · Total reported value $554.92M · Top-10 concentration 71.1% · Updated 2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.8% · 4 new · 4 cut · 9 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Eagle Health Investments LP disclosed 22 equity positions with a combined reported value of $554.92M. The filing implies a focused portfolio: its ten largest positions account for 71.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were ARGX ($73.45M), ICLR ($45.02M), ISRG ($44.14M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+4.0pp) and away from Other (-1.6pp), Technology (-2.5pp).

Versus the prior quarter, Eagle Health Investments LP opened 4 new positions, trimmed 4 and fully exited 9, a turnover rate of 54.8% of positions. The portfolio's overlap with the prior quarter was 58% of names.

The largest new positions opened in Q3 2026 were UTHR ($43.18M), ROIV ($32.15M), REPL ($9.60M).

Of the 9 positions fully exited versus the prior quarter, the largest were BMRN ($35.74M), ILMN ($32.95M), RARE ($29.52M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • UTHR UNITED THERAPEUTICS CORP DEL · $43.18M
  • ROIV ROIVANT SCIENCES LTD · $32.15M
  • REPL REPLIMUNE GROUP INC · $9.60M
  • SMMT SUMMIT THERAPEUTICS INC · $2.61M

Fully Exited (vs previous quarter)

  • BMRN BIOMARIN PHARMACEUTICAL INC · prev qtr: $35.74M
  • ILMN ILLUMINA INC · prev qtr: $32.95M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $29.52M
  • IONS IONIS PHARMACEUTICALS INC · prev qtr: $15.43M
  • TEM TEMPUS AI INC · prev qtr: $14.85M
  • ATAI Ataibeckley Inc CVR · prev qtr: $9.01M
  • NTRA NATERA INC · prev qtr: $4.30M
  • LLY ELI LILLY & CO · prev qtr: $2.39M

Insider Transactions (Form 4)

Latest Eagle Health Investments LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eagle Health Investments LP, based in Greenwich, CT, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 27 positions worth $603.31M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-121917 (status: Approved), registered 2021-07-29
  • Regulatory AUM (Form ADV): $605.26M as of 2026-03-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 27 positions · $603.31M reported value (Q2 2026)
  • Top 10 holdings = 66.1% of reported value
  • Largest position: ARGX (ARGENX SE FUNSPONSORED ADR 1 ADR REPS 1 ORD SHS) at 11.8%
  • Average position size: $22.34M

Sector Tilt

  • Health Care 96.0%
  • Information Technology 2.5%
  • (classified holdings cover 98% of value)

Quarterly Activity

  • Q2 2026: 5 new, 9 added, 4 reduced, 5 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively rotating into high-growth biotech/healthcare names (e.g., ISRG, ROIV) while reducing exposure to established but underperforming positions (e.g., ICLR, GH), signaling a bullish tilt on innovative healthcare technologies. 2. Key moves: - Added: ISRG (+2372.6% QoQ shares), SRRK (+1.1% QoQ shares), ASND (+11.7% QoQ shares). - Reduced: ICLR (-14.1% QoQ shares), INSM (-6.6% QoQ shares), GH (-50.0% QoQ shares). - New: UTHR, ROIV. 3. Portfolio structure: Highly active, concentrated in Health Care (100% of top 10), with a preference for high-risk, high-reward biotech/medtech stocks (e.g., gene therapy, surgical robotics). 4. Per-holding one-liner: - ARGX: Argenx SE (immunology) – *unverified*. - ICLR: ICON (clinical research) – *unverified*. - ISRG: Intuitive Surgical (surgical robotics). - UTHR: United Therapeutics (pulmonary/hypertension drugs). - INSM: Insmed (rare lung disease). - PTGX: Protagonist (inflammation/immunology). - ROIV: Roivant Sciences (biotech innovation). - SRRK: Scholar Rock (muscle biology). - ASND: Ascendis Pharma (growth disorders). - GH: Guardant Health (cancer diagnostics). 5. Style summary: Aggressive healthcare-focused fund doubling down on disruptive biotech/medtech while trimming laggards.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-16 17:16

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 76.59K $73.45M 13.23%
13.23%
Hold
2 264.81K $45.02M 8.11%
8.11%
Reduce
3 108.55K $44.14M 7.95%
7.95%
Add
4 79.68K $43.18M 7.78%
7.78%
New
5 358.70K $40.94M 7.38%
7.38%
Reduce
6 248.32K $34.99M 6.30%
6.30%
Hold
7 879.19K $32.15M 5.79%
5.79%
New
8 561.53K $27.13M 4.89%
4.89%
Add
9 118.63K $27.03M 4.87%
4.87%
Add
10 150.30K $26.81M 4.83%
4.83%
Reduce
11 2.06M $25.63M 4.62%
4.62%
Hold
12 120.35K $24.70M 4.45%
4.45%
Hold
13 1.18M $23.57M 4.25%
4.25%
Hold
14 459.11K $20.04M 3.61%
3.61%
Add
15 119.27K $13.33M 2.40%
2.40%
Reduce
16 297.30K $12.05M 2.17%
2.17%
Hold
17 65.05K $11.99M 2.16%
2.16%
Hold
18 131.34K $11.56M 2.08%
2.08%
Hold
19 724.79K $9.60M 1.73%
1.73%
New
20 235.09K $3.60M 0.65%
0.65%
Hold
21 154.49K $2.61M 0.47%
0.47%
New
22 46.30K $1.40M 0.25%
0.25%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 21% of its Top-10 each quarter and backtests at F1 79% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 79% · recall 79% · F1 79% · avg rank error 2.0 · Top-10 turnover 21%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 90% 90% 90% ILMN · ICLR · NTRA · DXCM · IQV · UTHR · DHR · ARGX · ALNY · INSP NTRA · ICLR · ILMN · UTHR · DXCM · ARGX · IQV · DHR · INSP · TMDX
2024-Q2 70% 70% 70% NTRA · ILMN · ICLR · UTHR · DXCM · ARGX · IQV · DHR · INSP · TMDX UTHR · NTRA · ICLR · UNH · ARGX · INSM · ILMN · DXCM · IQV · EXAS
2024-Q3 80% 80% 80% UTHR · NTRA · ICLR · UNH · ARGX · INSM · ILMN · DXCM · EXAS · IQV NTRA · ILMN · ARGX · ICLR · INSM · EXAS · RARE · DXCM · UNH · BMRN
2024-Q4 90% 90% 90% NTRA · ILMN · EXAS · ARGX · INSM · ICLR · RARE · BMRN · DXCM · INSP NTRA · ARGX · ILMN · ICLR · INSM · BMRN · RARE · INSP · DXCM · NBIX
2025-Q1 90% 90% 90% NTRA · ICLR · ILMN · ARGX · INSM · BMRN · RARE · INSP · DXCM · NBIX ARGX · NTRA · ICLR · INSM · ILMN · BMRN · NBIX · DXCM · RARE · ALNY
2025-Q2 90% 90% 90% ARGX · ICLR · NTRA · INSM · BMRN · NBIX · ILMN · DXCM · RARE · PRCT INSM · ARGX · NTRA · ILMN · ICLR · NBIX · DXCM · RARE · BMRN · UNH
2025-Q3 80% 80% 80% INSM · ARGX · NTRA · ILMN · ICLR · NBIX · DXCM · RARE · BMRN · UNH ARGX · INSM · NTRA · ICLR · ILMN · NBIX · RARE · BMRN · GH · EXAS
2025-Q4 80% 80% 80% ARGX · INSM · ICLR · NTRA · ILMN · NBIX · RARE · BMRN · GH · SRRK ARGX · ICLR · NTRA · INSM · ILMN · GH · NBIX · BMRN · FTRE · BBIO
2026-Q1 70% 70% 70% ARGX · ICLR · NTRA · INSM · GH · ILMN · NBIX · FTRE · BMRN · BBIO XBI · ARGX · ICLR · INSM · GH · BMRN · NTRA · SRRK · ILMN · TERN
2026-Q2 60% 60% 60% XBI · ARGX · ICLR · INSM · BMRN · GH · SRRK · TERN · NTRA · ASND ARGX · ICLR · GH · INSM · BMRN · ILMN · SRRK · PTGX · RARE · CMPS
2026-Q3 ★ 70% 70% 70% ARGX · ICLR · GH · INSM · BMRN · PTGX · ILMN · SRRK · ASND · RARE ARGX · ICLR · ISRG · UTHR · INSM · PTGX · ROIV · SRRK · ASND · GH

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-13. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-13 Trading days32 Holdings12 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.

Portfolio return+2.33%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return+16.05%vs benchmark
Barra annualised vol26.6%Model estimate
Realised vol27.6%Annualised in window
Weighted beta0.74Raw exposure
Factor / specific risk68% / 32%Share of variance
Top-10 concentration90.0%Of reported value
Portfolio value (start = 100)78.185.793.2100.7108.210-0110-2311-13Eagle Health Investments LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+2.33%Disclosed long book
QQQ synthetic benchmark-13.72%Liquidity-weighted constituents
Model universe, equal weight+0.30%Opportunity-cost reference
Excess return+16.05%Portfolio − benchmark
Arithmetic return sum+2.77%Difference vs compounded is the cross term
Weighted raw beta0.74Weighted holding betas
Realised volatility (annualised)27.60%Daily returns in window
Barra model volatility (annualised)26.56%Factor + specific
Factor share of variance67.7%Barra factors
Specific share of variance32.3%Stock residuals
Reported value$436.1M13F long US equity

2. Return attribution

The +2.77% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +2.15% 77.5%
Momentum & Growth 3 -2.44% -87.9%
Volatility & Tail Risk 7 +3.49% 125.9%
Industry 12 +8.12% 293.0%
Specific 1 -8.55% -308.5%
Return attribution (style + industry, %)-8.8-4.4+0.0+4.4+8.8Amihud Illiquidity-0.48Beta-0.61Turnover+0.69Leverage (Downside Vol)+0.74Mid Cap-0.76Max Drawdown+0.80Non-linear Size+0.91Size+1.73Momentum-2.41Residual Volatility+3.59Historical Volatility-4.17Skewness-4.40Kurtosis+7.54Health Care+8.12
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +8.12% +8.12% 293.0%
Kurtosis Style +1.08 +6.97% +7.54% 272.0%
Residual Volatility Style +1.35 +2.66% +3.59% 129.4%
Size Style -0.95 -1.83% +1.73% 62.6%
Non-linear Size Style +0.99 +0.91% +0.91% 32.7%
Max Drawdown Style -0.41 -1.96% +0.80% 28.9%
Leverage (Downside Vol) Style -0.41 -1.82% +0.74% 26.7%
Turnover Style -0.15 -4.77% +0.69% 24.9%
Growth Style +0.04 +1.57% +0.06% 2.2%
Liquidity Style +0.24 +0.22% +0.05% 1.9%
Short-term Reversal Style -0.11 +0.79% -0.09% -3.1%
Amihud Illiquidity Style +1.19 -0.40% -0.48% -17.3%
Beta Style -0.13 +4.85% -0.61% -22.0%
Mid Cap Style +0.45 -1.69% -0.76% -27.3%
Momentum Style +0.72 -3.34% -2.41% -87.0%
Historical Volatility Style +0.32 -12.86% -4.17% -150.3%
Skewness Style +1.04 -4.21% -4.40% -158.8%
Specific Specific — — -8.55% -308.5%

3. Risk attribution

Annualised volatility is 26.56%; factor risk explains 67.7% of variance and specific risk 32.3%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-39.9-20.0+0.0+20.0+39.9Beta-0.46Short-term Reversal+0.37Historical Volatility+0.70Mid Cap+1.28Kurtosis+3.37Amihud Illiquidity+3.59Max Drawdown+4.04Skewness+4.82Size+5.84Momentum+7.42Specific+32.26Health Care+36.97
Factor Type Exposure Share of variance Vol contribution Share of vol
Health Care Industry +1.00 37.0% +9.82% 9.8%
Specific Specific — 32.3% +8.57% 8.6%
Momentum Style +0.72 7.4% +1.97% 2.0%
Size Style -0.95 5.8% +1.55% 1.6%
Skewness Style +1.04 4.8% +1.28% 1.3%
Max Drawdown Style -0.41 4.0% +1.07% 1.1%
Amihud Illiquidity Style +1.19 3.6% +0.95% 0.9%
Kurtosis Style +1.08 3.4% +0.89% 0.9%
Mid Cap Style +0.45 1.3% +0.34% 0.3%
Historical Volatility Style +0.32 0.7% +0.18% 0.2%
Short-term Reversal Style -0.11 0.4% +0.10% 0.1%
Beta Style -0.13 -0.5% -0.12% -0.1%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.3-0.30.61.52.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -0.95 +2.10 -3.05
Non-linear Size +0.99 +1.68 -0.69
Mid Cap +0.45 +0.13 +0.32
Beta -0.13 +1.29 -1.42
Momentum +0.72 +0.72 +0.01
Short-term Reversal -0.11 -0.64 +0.53
Residual Volatility +1.35 -0.40 +1.75
Historical Volatility +0.32 +0.86 -0.54
Liquidity +0.24 +0.11 +0.12
Amihud Illiquidity +1.19 +1.16 +0.03
Turnover -0.14 +0.21 -0.35
Growth +0.04 +0.58 -0.54
Leverage (Downside Vol) -0.41 +0.14 -0.55
Skewness +1.04 +0.24 +0.81
Kurtosis +1.08 +0.21 +0.87
Max Drawdown -0.41 -0.08 -0.33

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -19.18% +4.32% +14.12% -14.12% +14.12%
Health Care 100.0% 1.7% +1.60% +9.16% +22.08% -0.13% -7.43% +1.44%
Communication Services 0.0% 2.6% +0.00% -15.54% +0.06% +0.41% -0.41% +0.41%
Utilities 0.0% 0.8% +0.00% +11.58% -0.20% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.58% -0.24% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.56% -1.66% -0.49% +0.49% -0.49%
Industrials 0.0% 11.1% +0.00% +7.16% -2.27% -0.80% +0.80% -0.80%
Total +21.99% +12.85% -20.42% +14.42%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
ARGX ARGENX SE Health Care 16.84% +0.12% +0.02% Hold
ICLR ICON PUB LTD CO Health Care 10.32% +14.51% +1.50% Reduce
ISRG INTUITIVE SURGICAL INC Health Care 10.12% +9.09% +0.92% Add
UTHR UNITED THERAPEUTICS CORP DEL Health Care 9.90% +9.09% +0.90% New
INSM INSMED INC Health Care 9.39% +6.15% +0.58% Reduce
PTGX PROTAGONIST THERAPEUTICS INC Health Care 8.02% -7.05% -0.57% Hold
ROIV ROIVANT SCIENCES LTD Health Care 7.37% +8.09% +0.60% New
SRRK SCHOLAR ROCK HLDG CORP Health Care 6.22% -10.59% -0.66% Add
GH GUARDANT HEALTH INC Health Care 6.15% -14.95% -0.92% Reduce
RVMD REVOLUTION MEDICINES INC Health Care 5.66% -16.06% -0.91% Hold
FTRE FORTREA HLDGS INC COMMON STOCK Health Care 5.40% +1.25% +0.07% Hold
BSX BOSTON SCIENTIFIC CORP Health Care 4.59% +1.58% +0.07% Add
Contribution rank Symbol Sector Weight Return Contribution
1 ICLR Health Care 10.32% +14.51% +1.50%
2 ISRG Health Care 10.12% +9.09% +0.92%
3 UTHR Health Care 9.90% +9.09% +0.90%
4 ROIV Health Care 7.37% +8.09% +0.60%
5 INSM Health Care 9.39% +6.15% +0.58%
6 BSX Health Care 4.59% +1.58% +0.07%
7 FTRE Health Care 5.40% +1.25% +0.07%
8 ARGX Health Care 16.84% +0.12% +0.02%
9 PTGX Health Care 8.02% -7.05% -0.57%
10 SRRK Health Care 6.22% -10.59% -0.66%
11 RVMD Health Care 5.66% -16.06% -0.91%
12 GH Health Care 6.15% -14.95% -0.92%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned +2.33%, versus -13.72% for the QQQ synthetic benchmark — an excess of +16.05%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +8.12%, Kurtosis +7.54%, Residual Volatility +3.59%; the largest drags came from Skewness -4.40%, Historical Volatility -4.17%, Momentum -2.41%. Specific (stock-level) return contributed -8.55%.
  3. Risk attribution: Barra model volatility is 26.56% annualised; factor risk explains 68% of variance and specific risk 32%. The largest factor risk sources are Health Care 37.0%, Momentum 7.4%, Size 5.8%.
  4. Style tilt: size -0.95, momentum +0.72, volatility +0.32, liquidity +0.24; the weighted raw beta is 0.74. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +21.99%, selection +12.85% and interaction -20.42%.
  6. Concentration: the top-10 positions are 90.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Eagle Health Investments LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Eagle Health Investments LP reported 22 equity positions worth $554.92M in aggregate; its largest disclosed positions were ARGX ($73.45M), ICLR ($45.02M), ISRG ($44.14M).

How large is Eagle Health Investments LP's portfolio?

Eagle Health Investments LP reported $554.92M of long equity holdings across 22 positions as of 2026-Q3. Top-10 holdings account for 71.1% of reported value.

What is Eagle Health Investments LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eagle-health-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →